Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant bivalent HPV16/18 vaccine 2-dose vs 3-dose immunogenicity in adolescents and adults
CTR20150243Phase 2Completed
- Sponsor
- Shanghai Zerun Biotechnology Co., Ltd.
- Start
- Apr 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of human papillomavirus bivalent (16/18) vaccine in HPV16 infection (HPV16), human papillomavirus infection type 18, sponsored by Shanghai Zerun Biotechnology Co., Ltd.. Started Apr 2015; status: completed.
02
Drugs
human papillomavirus bivalent (16/18) vaccine
03
Conditions
HPV16 infection (HPV16)human papillomavirus infection type 18
Beyond the preview
Go deeper on CTR20150243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150243.